Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? Marianne Witten, MD, PhD, Hans-Jørgen Malling, MD, Lars.

Slides:

Advertisements

Similar presentations

Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy Ravi S. Swamy, MD, Neha Reshamwala,

Advertisements

Lower vitamin D status is closely correlated with eczema of the head and neck Seongmin Noh, MD, Chang Ook Park, MD, Jung Min Bae, MD, Jungsoo Lee, MD,

Clinical Application of Nasal Filters: An Observational Study on the Usability of Nasal Filters in Managing Seasonal Allergic Rhinitis Peter Kenney,

Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy Monica B. Arvidsson, MD, Olle.

Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms Anna Slovick, MRCS, Abdel Douiri, PhD,

Lower vitamin D status is closely correlated with eczema of the head and neck Seongmin Noh, MD, Chang Ook Park, MD, Jung Min Bae, MD, Jungsoo Lee, MD,

Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,

Allergen immunotherapy: A practice parameter third update

Risk of an asthma exacerbation after bariatric surgery in adults

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial Stephen.

Ibrutinib, a Bruton’s tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil.

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults Peter S. Creticos, MD, Jennifer Maloney,

Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy Gabriela Senti, MD, Nicole Graf, PhD, Susanne Haug, MD, Nadine.

Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.

Evaluation of BCG administration as an adjuvant to specific immunotherapy in asthmatic children with mite allergy Andrea Cohon, MD, L. Karla Arruda,

Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32 Verena Niederberger, MD, Angela Neubauer, PhD,

Birch pollen immunotherapy results in long-term loss of Bet v 1–specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies

Is 9 more than 2 also in allergic airway inflammation?

Clinical Application of Nasal Filters: An Observational Study on the Usability of Nasal Filters in Managing Seasonal Allergic Rhinitis Peter Kenney,

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial Stephen.

Safety of allergen immunotherapy: A 10-year prospective study

Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy Albrecht Bufe, PhD, MD, Peter Eberle, MD, Eivy.

Response to sublingual immunotherapy with grass pollen extract: Monotherapy versus combination in a multiallergen extract Sheila M. Amar, MD, Ronald.

Intralymphatic immunotherapy with 2 concomitant allergens, birch and grass: A randomized, double-blind, placebo-controlled trial Laila Hellkvist, MD,

A randomized controlled study of peanut oral immunotherapy: Clinical desensitization and modulation of the allergic response Pooja Varshney, MD, Stacie.

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

T-cell involvement in delayed-type hypersensitivity reactions to infliximab Maria Jose Torres, MD, PhD, Patrícia Chaves, PhD, Inmaculada Doña, MD, Natalia.

Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms Anna Slovick, MRCS, Abdel Douiri, PhD,

Physician needs in health informatics: Just ask the docs

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

Lower vitamin D status is closely correlated with eczema of the head and neck Seongmin Noh, MD, Chang Ook Park, MD, Jung Min Bae, MD, Jungsoo Lee, MD,

Daily home measurements of exhaled nitric oxide in asthmatic children during natural birch pollen exposure Signe Vahlkvist, MD, Marianne Sinding, Kirsten.

Debra J. Palmer, PhD, Thomas R. Sullivan, BMa&CompSc(Hons), Michael S

Phillip Lieberman, MD, Michael Tankersley, MD

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Allergen-specific immunotherapy with recombinant grass pollen allergens Marek Jutel, MD, Lothar Jaeger, MD, Roland Suck, PhD, Hanns Meyer, Dipl Math,

Reduction in allergen-specific IgE binding as measured by microarray: A possible surrogate marker for effects of specific immunotherapy Eva Wollmann,

Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis Stephen R. Durham,

Evaluation of Allergen Immunotherapy

Cockroach allergens: Coping with challenging complexity

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Advances in the approach to the patient with food allergy

House dust mite sublingual immunotherapy: Results of a US trial

High prevalence of severe asthma in a large random population study

Association between specific timothy grass antigens and changes in TH1- and TH2-cell responses following specific immunotherapy Véronique Schulten, PhD,

Sara Paveglio, PhD, MS, Erin Bennett, MS, Kelly L. Hawley, PhD, Adam P

Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab Donald W. MacGlashan,

Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years Ronald Dahl, MD,

Long-term clinical efficacy in grass pollen–induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet Stephen.

Piotr Kuna, MD, Jadwiga Kaczmarek, MD, Maciej Kupczyk, MD

Nasal inflammatory mediators and specific IgE production after nasal challenge with grass pollen in local allergic rhinitis Carmen Rondón, MD, PhD, Javier.

Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis Philippe-Jean Bousquet, MD, Christophe Combescure, PhD,

In vivo effects of glucocorticoids on IgE production

Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber

Thunderstorm-related asthma attacks

Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity James N. Francis, PhD, Louisa.

Guus A. Westerhof, MD, Elise M. Vollema, MD, Els J

Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy Johannes Martin Schmid, MD, Peter Adler Würtzen, PhD,

Macrolide antibiotics and asthma treatment

Asthma: The past, future, environment, and costs

Interrupting IL-6–receptor signaling improves atopic dermatitis but associates with bacterial superinfection Alexander A. Navarini, MD, PhD, Lars E.

Placental transfer of allergen-specific IgG but not IgE from a specific immunotherapy– treated mother Sabine Flicker, PhD, Katharina Marth, MD, Heinz.

Fiftieth Annual Meeting of the American Academy of Allergy and Immunology: Anaheim, California, March 1994 Lawrence M. Lichtenstein, MD, PhD Journal.

Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen Piyush Patel, MD, Tom Holdich, MBBS,

The GILL study: Glycerin-induced local reactions in immunotherapy

Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule

Natural history of cow’s milk allergy

Presentation transcript:

Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? Marianne Witten, MD, PhD, Hans-Jørgen Malling, MD, Lars Blom, PhD, Britta C. Poulsen, MSc, Lars K. Poulsen, PhD Journal of Allergy and Clinical Immunology Volume 132, Issue 5, Pages 1248-1252.e5 (November 2013) DOI: 10.1016/j.jaci.2013.07.033 Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Primary outcome for the posttreatment season. Grass pollen count visual analog scale (VAS) and RQLQ scores for the pretreatment and posttreatment seasons. Pollen counts were obtained from the Danish Meteorological Institute (upper left). The total amount of pollen in the posttreatment season was 1885/mm3, and that for the pretreatment season was 1953/m3. The season was predefined from June 1 to August 31, 2011, including 91% of the total amount. The peak season (shaded area) was weeks 23, 24, and 25, including 56% of the total pollen count. MS, Medication score during the season; NS, not significant; SS, symptom score during the season. *P < .05 and ***P < .0005. Journal of Allergy and Clinical Immunology 2013 132, 1248-1252.e5DOI: (10.1016/j.jaci.2013.07.033) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Paraclinical parameters: intradermal skin tests (IDT) and IgE, IgG4, T-cell intracellular cytokine, and regulatory T-cell marker measurements. IgE and IgG4 concentrations and posttreatment/pretreatment ratios (logarithmic scale) are shown. The ratio increased significantly after treatment in the treated groups. Blood samples for determination of allergen-specific IgE and IgG4 levels by using CAP were drawn before treatment, after 3 and 6 treatments, and after the posttreatment season. Intracellular T-cell cytokines after allergen or tetanus toxoid stimulation of PBMCs were identified. *P < .05, **P < .005, and ***P < .0005. Journal of Allergy and Clinical Immunology 2013 132, 1248-1252.e5DOI: (10.1016/j.jaci.2013.07.033) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E1 Participant flowchart. *Reduced number because of some patients with inadequate diary data. Journal of Allergy and Clinical Immunology 2013 132, 1248-1252.e5DOI: (10.1016/j.jaci.2013.07.033) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions